Clinical features of therapy-related acute lymphoblastic leukemia (t-ALL), and comparison of clinical outcomes between t-ALL and de novo ALL



Characteristics of the t-ALL cohort

Original	diagnosis	prior to	t-ALL	onset
E60/ Sa	lid cancor			

56% Solid cancer

35% Hematological cancer

2% Combined solid and hematological cancers

6% Non-malignant diseases treated with cytotoxic therapies

Cytotoxic therapies prior to t-ALL onset

38% Only chemotherapy

28% Only radiotherapy

34% Chemotherapy + radiation

18% Autologous hematopoietic cell transplant

14% Immunomodulatory agents + chemotherapy

Hematopoietic cell transplantation (HCT)	Median follow-up	2-year OS	non-relapse mortality
t-ALL 49		53.4%	28.5%
De novo ALL 6564	25.5 months (range 0.03-198.3)	58.9%	22.7%
	(runge 0.03 130.3)	p=0.68	p=0.38

Allogeneic hematopoietic cell transplantation outcomes were comparable for t-ALL and de novo ALL